SELLAS Life Sciences Group, Inc. (SLS) SEC Filings & Earnings Calls

Clinical trial failure risk: Phase 3 REGAL trial results could be negative, delaying or preventing BLA.

“Phase 3 REGAL trial of GPS in AML; final analysis pending 80th event.”

Financing risk: Pre-revenue company with increasing R&D spend; cash runway may require future capital raises.

“Net loss $9.6M in Q2 2026 vs $6.6M in Q2 2025; cash $138.3M.”

Clinical trial failure risk

“Because the final analysis is event driven, it is difficult to predict with any certainty and it may occur at a different time than currently expected.” · word for word

Dependence on regulatory approval

“We may never succeed in achieving regulatory approval for any of our current or future product candidates.” · word for word

Cash burn and need for future financing

“If actual results are different from management's estimates, we may need to seek additional strategic or financing opportunities sooner than would otherwise be expected.” · word for word

Arbitration loss imposes $1.0M legal fee liability and removes disputed milestone payments, potentially reducing future revenue from license agreement.

“On July 24, 2026, the sole arbitrator... rendered a decision dismissing the Company’s claims... allocated a portion of 3D Medicines’ legal fees and costs in the amount of approximately $1.0 million to be paid by the Company.”

Potential retention risk or change-of-control preparedness; no immediate financial impact disclosed.

“Severance agreements include change-of-control provisions and lump sum payments, but no departure or performance issue indicated.”

Significant dilution from warrant exercises; high share count for a pre-revenue biotech.

“196.6M shares outstanding; $28.7M raised from warrant exercises.”

Clinical trial outcome uncertainty

“Because the final analysis is event driven, it is difficult to predict with any certainty and it may occur at a different time than currently expected.” · word for word

Arbitration dispute with partner

“In December 2023, we announced that we had commenced a binding arbitration proceeding against 3D Medicines to resolve a dispute regarding, among other things, the trigger and payment of relevant milestone payments due to us under the 3D Medicines Agreement.” · word for word

Clinical trial risk: REGAL trial approaching 80th event; outcome uncertain.

“78 Events have Occurred in the Trial as of May 11, 2026” · word for word

Low insider ownership

“All current executive officers and directors as a group (8 persons): 2,421,658 shares, 1.3%” · word for word

Dependence on equity compensation for retention

“If the authorized shares are depleted prior to the expiration date of the 2023 Equity Plan, we will not be able to continue to offer a long-term incentive program that utilizes equity awards, which could put us at a competitive disadvantage in recruiting and retaining talent.” · word for word

Clinical trial outcome risk; REGAL final analysis pending.

“final analysis will be conducted once 80 events (deaths) are reached”

NOL Limitation Risk

“The Merger constituted an ownership change and as such, our ability to use our NOL carryforwards is materially limited, which may harm our future operating results by effectively increasing our future tax obligations.” · word for word

Dilution Risk

“As of December 31, 2025, we had reserved for issuance 58,481,974 shares of our common stock issuable upon the exercise of outstanding warrants” · word for word

Delisting Risk

“If our common stock is delisted, it could reduce the price of our common stock and the levels of liquidity available to our stockholders.” · word for word

Dilution from warrant exercises; share count increased.

“179,536,724 shares outstanding as of March 11, 2026”

Preliminary cash figures subject to change; no revenue or earnings data provided.

“Amount is unaudited and preliminary and may differ materially from final financial statements.”

Going concern risk mitigated by recent capital raises

“The Company expects its cash and cash equivalents, together with the approximately $29.1 million in net proceeds from the October 2025 Inducement, will be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements” · word for word

Clinical trial failure risk

“The final analysis will be conducted once 80 events (deaths) are reached. We anticipate that 80 events will be reached this year. Because the final analysis is event driven, it is difficult to predict with any certainty and it may occur at a different time than currently expected.” · word for word

Arbitration dispute with 3D Medicines

“In December 2023, the Company commenced a binding arbitration proceeding against 3D Medicines, which involves, among other things, the trigger and payment of certain milestone payments due to the Company.” · word for word

Dilution risk from outstanding warrants and options

“Total common stock reserved for future issuance 70,177 (in thousands) at September 30, 2025” · word for word

No revenue and history of losses

“Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of September 30, 2025, has an accumulated deficit of $267.3 million.” · word for word

Clinical trial outcome risk; REGAL final analysis pending.

“final analysis will be conducted once 80 events (deaths) are reached” · word for word

Dilution from warrant inducement; terms not disclosed.

“Form of Inducement Warrant” · word for word